Division of Cardiology, UCLA Medical Center, Los Angeles, CA, United States of America.
Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.
Cardiovasc Revasc Med. 2021 Nov;32:43-49. doi: 10.1016/j.carrev.2020.12.034. Epub 2020 Dec 31.
The ideal drug-eluting stent (DES) for the treatment of unprotected left main coronary artery (ULMCA) is unknown. We compared percutaneous coronary intervention (PCI) using durable polymers versus early-generation, thicker strutted and coated bioabsorbable polymers for ULMCA disease.
Patients who underwent ULMCA PCI (893 patients) from April 2008 to November 2014 were identified from the Grand-DES registry. The primary end point was 3-year target lesion failure (TLF) after propensity score matching.
The final analysis included 754 patients (84.4%) and 139 patients (15.6%) in the durable and bioabsorbable polymer group, respectively. The groups differed significantly in lesion and procedural characteristics. Propensity score-matched analysis revealed a trend toward a lower 3-year TLF in the durable polymer group (log rank p=0.071). Independent predictors of 3-year TLF were chronic kidney disease, presentation with acute myocardial infarction, and a two-stenting technique for ULMCA lesions. Definite/probable stent thrombosis rates at 3-years were low in both groups (0.8% vs. 0.7%, p=0.925).
The safety of ULCMA PCI was excellent, and durable and bioabsorbable polymer DES provided similar clinical outcomes at 3-year follow-up. Landmark analysis revealed that the durable polymer group had a lower TLF rate from 9 months. Further studies are needed to confirm these results.
用于治疗无保护左主干冠状动脉(ULMCA)的理想药物洗脱支架(DES)尚不清楚。我们比较了使用耐用聚合物与早期、更厚的支撑和涂层可生物吸收聚合物治疗 ULMCA 疾病的经皮冠状动脉介入治疗(PCI)。
从 2008 年 4 月至 2014 年 11 月,从 Grand-DES 注册中心确定了接受 ULMCA PCI 的患者(893 例患者)。主要终点是倾向性评分匹配后 3 年的靶病变失败(TLF)。
最终分析包括 754 例患者(84.4%)和 139 例患者(15.6%)分别在耐用聚合物组和可生物吸收聚合物组。两组在病变和手术特征方面存在显著差异。倾向性评分匹配分析显示,耐用聚合物组 3 年 TLF 发生率呈下降趋势(对数秩检验 p=0.071)。3 年 TLF 的独立预测因素为慢性肾脏病、急性心肌梗死发作和 ULMCA 病变的双支架技术。两组 3 年明确/可能的支架血栓形成率均较低(0.8%比 0.7%,p=0.925)。
ULMCA PCI 的安全性非常好,耐用聚合物和可生物吸收聚合物 DES 在 3 年随访时提供了相似的临床结果。里程碑分析显示,耐用聚合物组从 9 个月开始 TLF 率较低。需要进一步的研究来证实这些结果。